1. Opening Hook
When your annual health check-up costs less than your cab ride to the lab, you know competition’s gone viral. 🧪 Amid price wars and post-pandemic malaise, Metropolis somehow pulled a 23% revenue growth — and still had breath left to brag about AI chatbots and “genomic synergies.” Chairman Ameera Shah called it “steady growth,” but it felt more like a well-timed caffeine rush. With B2C at 59% and Core Diagnostics integration still in ICU, the company’s trying to prove it’s not just another blood test factory. Stick around — this call had more tech talk than a startup pitch.
2. At a Glance
- Revenue up 23%: Doctors’ prescriptions may slow, but Metropolis didn’t skip its growth meds.
- EBITDA Margin 25.4%: Healthy, though Core Diagnostics’ weaker pulse pulled averages down.
- PAT ₹53 crore (up 13.6%): Profits jogged, didn’t sprint.
- Organic EBITDA Margin 26.8%: 60 bps lift — efficiency is apparently the new multivitamin.
- B2C share 59%: Consumers still bleeding for convenience.
- Stock? Traders smiled — “AI-led diagnostics” sounded futuristic enough.
3. Management’s Key Commentary
Ameera Shah: “We are building a resilient, future-ready diagnostics company.”
(Translation: We’ve said this for five years, but this time we’ve added AI.) 😏
Surendran Chemmenkotil: “Margins improved by 60 bps YoY to 26.8%.”
(Translation: We’ve upgraded from mild anemia to stable vitals.)
Sameer Patel: “Core Diagnostics moved from breakeven to high-single-digit margins.”
(Translation: Still in rehab, but at least the patient’s breathing.)
Ameera Shah: “No new
acquisitions for 6–9 months; focus on organic growth.”
(Translation: Wallet says stop, strategy says spin it as discipline.)
Surendran: “Added 200 new centres, 300 more coming.”
(Translation: When in doubt, expand faster than your margins.)
Ameera Shah: “We’re integrating AI for productivity and customer experience.”
(Translation: The robots can’t draw blood yet, but they can schedule your test politely.)
Ameera Shah: “Our moat is quality, accessibility and empathy.”
(Translation: The moat’s still being dug, but at least the PR’s ready.)
4. Numbers Decoded
| Metric | Q2 FY26 | YoY Growth | Comment |
|---|---|---|---|
| Revenue (Group) | ₹429 Cr | +23% | Strong mix of TruHealth, Specialty, and mild fever season help. |
| EBITDA Margin (Group) | 25.4% | Flat-ish | Core Diagnostics dilution drags. |
| EBITDA Margin (Organic) | 26.8% | +60 bps | Operational steroids working. |
| PAT (Group) | ₹52.9 Cr | +13.6% | Solid but not viral. |
| Patient Volume (Organic) | 3.6 Mn | +6% | Fewer mosquitoes, fewer tests. |
| Test Volume (Organic) | 7.4 Mn | +6% | TruHealth offsets lost dengue dreams. |
| B2C:B2B Mix | 59:41 | Stable | Consumers dominate; hospitals follow. |
Margins improved thanks to automation, better test mix, and less fever dependence. Translation: less monsoon, more money.
